BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 20463804)

  • 1. Bimatoprost in the treatment of eyelash hypotrichosis.
    Law SK
    Clin Ophthalmol; 2010 Apr; 4():349-58. PubMed ID: 20463804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of hypotrichosis of the eyelashes: Focus on bimatoprost.
    Fagien S
    Clin Cosmet Investig Dermatol; 2010 Apr; 3():39-48. PubMed ID: 21437058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bimatoprost for the treatment of eyelash, eyebrow and scalp alopecia.
    Barrón-Hernández YL; Tosti A
    Expert Opin Investig Drugs; 2017 Apr; 26(4):515-522. PubMed ID: 28264599
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of hypotrichosis of the eyelashes: focus on bimatoprost.
    Fagien S
    Plast Surg Nurs; 2015; 35(2):82-91. PubMed ID: 26020474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of LATISSE (bimatoprost 0.03 per cent topical solution) on the ocular surface.
    Bitton E; Courey C; Giancola P; Diaconu V; Wise J; Wittich W
    Clin Exp Optom; 2017 Nov; 100(6):583-589. PubMed ID: 28122407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias.
    Khidhir KG; Woodward DF; Farjo NP; Farjo BK; Tang ES; Wang JW; Picksley SM; Randall VA
    FASEB J; 2013 Feb; 27(2):557-67. PubMed ID: 23104985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis.
    Chanasumon N; Sriphojanart T; Suchonwanit P
    Drug Des Devel Ther; 2018; 12():365-372. PubMed ID: 29503529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of bimatoprost solution 0.03% topical application in patients with chemotherapy-induced eyelash loss.
    Ahluwalia GS
    J Investig Dermatol Symp Proc; 2013 Dec; 16(1):S73-6. PubMed ID: 24326568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects.
    Borchert M; Bruce S; Wirta D; Yoelin SG; Lee S; Mao C; VanDenburgh A
    Clin Ophthalmol; 2016; 10():419-29. PubMed ID: 27022239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Topical bimatoprost in the treatment of eyelash loss in alopecia totalis and universalis: A prospective, open-label study.
    Ricar J; Cetkovska P; Hordinsky M; Ricarova R
    Dermatol Ther; 2022 Jun; 35(6):e15438. PubMed ID: 35278027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial.
    Glaser DA; Hossain P; Perkins W; Griffiths T; Ahluwalia G; Weng E; Beddingfield FC
    Br J Dermatol; 2015; 172(5):1384-94. PubMed ID: 25296533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review.
    Riahi RR; Cohen PR
    Cureus; 2018 May; 10(5):e2666. PubMed ID: 30042917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eyelash growth induced by topical prostaglandin analogues, bimatoprost, tafluprost, travoprost, and latanoprost in rabbits.
    Giannico AT; Lima L; Russ HH; Montiani-Ferreira F
    J Ocul Pharmacol Ther; 2013 Nov; 29(9):817-20. PubMed ID: 23981234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Revisiting the Safety of Prostaglandin Analog Eyelash Growth Products.
    Steinsapir KD; Steinsapir SMG
    Dermatol Surg; 2021 May; 47(5):658-665. PubMed ID: 33625141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Antiglaucoma Agent and EP2 Receptor Agonist Omidenepag Does Not Affect Eyelash Growth in Mice.
    Esaki Y; Katsuta O; Kamio H; Noto T; Mano H; Iwamura R; Yoneda K; Odani-Kawabata N; Morishima K; Shams NK
    J Ocul Pharmacol Ther; 2020 Sep; 36(7):529-533. PubMed ID: 32412835
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
    Fagien S; Walt JG; Carruthers J; Cox SE; Wirta D; Weng E; Beddingfield FC
    Aesthet Surg J; 2013 Aug; 33(6):789-98. PubMed ID: 23873891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertrichosis of the eyelashes caused by bimatoprost.
    Tosti A; Pazzaglia M; Voudouris S; Tosti G
    J Am Acad Dermatol; 2004 Nov; 51(5 Suppl):S149-50. PubMed ID: 15577756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced eyelashes: prescription and over-the-counter options.
    Jones D
    Aesthetic Plast Surg; 2011 Feb; 35(1):116-21. PubMed ID: 20730536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.
    Woodward DF; Wang JW; Poloso NJ
    Pharmacol Rev; 2013; 65(4):1135-47. PubMed ID: 23893067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies.
    Harii K; Arase S; Tsuboi R; Weng E; Daniels S; VanDenburgh A
    Aesthetic Plast Surg; 2014 Apr; 38(2):451-60. PubMed ID: 24643895
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.